A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 May 2019
Price : $35 *
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Losartan
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Arbor Pharmaceuticals
- 22 Mar 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.
- 11 Mar 2019 Planned End Date changed from 1 Aug 2020 to 1 Apr 2020.
- 11 Mar 2019 Planned primary completion date changed from 1 Feb 2020 to 1 Nov 2019.